Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers-Reference-Cited by-同舟云学术

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers

Published:2021-06-15 Issue:4 Volume:9 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Navani Vishal¹²^ORCID,Graves Moira C.²^ORCID,Marchett Giovana Celli¹,Mandaliya Hiren¹^ORCID,Bowden Nikola A.²^ORCID,Westhuizen Andre¹²

Affiliation:

1. Calvary Mater Hospital Newcastle Waratah NSW Australia

2. Centre for Drug Repurposing and Medicines Research University of Newcastle and Hunter Medical Research Institute Callaghan NSW Australia

Funder

Cancer Institute NSW

Hunter Medical Research Institute

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.808

Reference43 articles.

1. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

2. T-cell exhaustion in the tumor microenvironment

3. National Comprehensive Cancer Network.Cutaneous melanoma (Version 4.2020).https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed October 15 2020.

4. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

5. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors;The Oncologist;2023-04-03

2. T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications;Frontiers in Immunology;2023-02-20

3. A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood;Immunological Investigations;2022-10-27

4. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge;Cancer Research Communications;2022-08-17

5. Melanoma: An immunotherapy journey from bench to bedside;Cancer Immunotherapies;2022